Ella Daly, MB, BCh, BAO

Impact of Individual and Class of Concomitant Oral Antidepressant on the Efficacy and Safety of Esketamine Nasal Spray in Patients With Treatment Resistant Depression

Objective: Phase 3 trials have demonstrated the efficacy and safety of esketamine nasal spray (ESK) plus a newly initiated oral antidepressant (AD) for treatment-resistant depression (TRD...

Ibrahim Turkoz , PhD;

Jennifer Kern Sliwa , PharmD, BCPP;

Ella Daly , MB, BCh, BAO;

Jaskaran Singh , MD;

Stephane Borentain , MD;

Muideen Adigun , PharmD;

11/22/2019

Impact of Treatment With Esketamine Nasal Spray in Patients With Treatment Resistant Depression and Comorbid Anxiety: A Post-hoc Pooled Analysis of the TRANSFORM 1 and 2 Trials

Purpose: To evaluate the impact of esketamine (ESK) nasal spray in patients with treatment-resistant depression (TRD) and comorbid anxiety.

Ibrahim Turkoz , PhD;

Ella Daly , MB, BCh, BAO;

Stephane Borentain , MD;

Madhukar Trivedi , MD;

Michael Thase , MD;

Jaskaran Singh , MD;

Giacomo Salvadore , MD;

Maggie Fedgchin , PharmD;

H. Lynn Starr , MD, FAAP;

A. John Rush , MD;

11/22/2019

National Trends in the Prevalence of Major Depressive Disorder With Suicidal Ideation Among Adults Using National Survey on Drug Use and Health Data

Introduction: Although depression is a known risk factor for suicide, little is known about how the prevalence of co-occurring major depressive disorder (MDD) and suicidal ideation/behavi...

Ella Daly , MB, BCh, BAO;

Kun Wang , PhD;

Harsh Kuvadia ;

John J. Sheehan , PhD, MBA, RPh;

Jennifer Voelker , MS, PharmD;

Jacqueline Pesa , PhD, MPH;

Nancy Connolly , MPH;

Ayush Srivastava , BS ;

11/22/2019

Economic Burden of Treatment Resistant Depression in Privately Insured US Patients With Behavioral Comorbidities

BACKGROUND: Incremental economic burden of treatment resistant depression (TRD) in patients with behavioral comorbidities is largely unknown.

Craig Nelson , MD;

Carmine Rossi , PhD;

Ella Daly , MB, BCh, BAO;

Maryia Zhdanava , MA;

Harsh Kuvadia ;

Patrick Lefebvre , MA;

Dominic Pilon , MA;

Kruti Joshi , MPH, MD;

11/22/2019

How Well Do Real-World Clinical And Demographic Characteristics Predict Patient Health Questionnaire-9 Scores Among Patients With Treatment-Resistant Depression?

Background: Many real-world databases do not capture the Patient Health Questionnaire-9 (PHQ-9), a self-reported questionnaire used to measure depression severity. We created a model to p...

Xing Liu , MA;

Eros Papademetriou , MA;

Kruti Joshi , MPH, MD;

Ella Daly , MB, BCh, BAO;

Ravi Potluri ;

David Rotter ;

Harsh Kuvadia ;

John J. Sheehan , PhD, MBA, RPh;

Anandaroop Dasgupta , PhD, MS;

11/22/2019

Predictors of Response and Remission in Patients With Treatment-Resistant Depression Treated With Esketamine

Objective: Identify patient and disease characteristics associated with greater likelihood of achieving response and remission with esketamine nasal spray (ESK) plus a newly initiated ora...

Ibrahim Turkoz , PhD;

Ella Daly , MB, BCh, BAO;

Jaskaran Singh , MD;

David Williamson , PhD, MBA;

Jack Sheehan , PhD, MBA, RPh;

Kristy Tardieu , BSN, MBA;

03/01/2019

Response Rates of Esketamine Nasal Spray Plus an Oral Antidepressant Among Patients Not Meeting Study Criteria for Early Response to Treatment

Objective: Esketamine nasal spray (ESK) plus a newly initiated antidepressant (AD) reduces depression symptoms in patients with treatment-resistant depression (TRD), in a subset meeting s...

Samuel Wilkinson , MD, PhD;

Craig Nelson , MD;

Giacomo Salvadore , MD;

Ibrahim Turkoz , PhD;

Ella Daly , MB, BCh, BAO;

Jaskaran Singh , MD;

David Williamson , PhD, MBA;

Abigail Nash , MD, PhD;

Xiwu Lin , PhD;

Yevgen Tymofyeyev , PhD;

11/22/2019

Randomized, Double-Blind Study of Fixed-Dose Esketamine Nasal Spray Plus Oral Antidepressant vs. Active Control in Treatment-Resistant Depression

Aim: Compare efficacy and safety of fixed doses of esketamine nasal spray plus oral antidepressant (AD) to oral AD plus placebo nasal spray for treatment-resistant depression (TRD). Met...

Dawn Vitagliano , BA;

Michael Liebowitz , MD;

Arun Ravindran , MB, PhD, MSc;

Raphael Gaillard , MD, PhD;

Hans van den Ameele , MD;

Maurizio Fava , MD, PhD;

Ella Daly , MB, BCh, BAO;

Madhukar Trivedi , MD;

Wayne Drevets , MD;

Jaskaran Singh , MD;

Rosanne Lane , MD, MSc, MS;

Maggie Fedgchin , PharmD;

Pilar Lim , MD, PhD;

Pierre Blier , MD, PhD;

David Hough , MD;

Rama Melkote , MSc, MPH;

Husseini Manji , MD;

03/01/2019

Adverse Events Affecting Readiness for Discharge From the Clinical Setting After Esketamine Nasal Spray Administration

Objective: To describe clinical findings in patients considered not ready for discharge from clinical sites 2 hours after administration of esketamine nasal spray (ESK).

Leah Aluisio , PhD;

David Williamson , PhD, MBA;

Ella Daly , MB, BCh, BAO;

Michelle Han , PharmD;

Sheldon Preskorn , MD;

Jagadish Gogate , PhD;

H. Lynn Starr , MD, FAAP;

Andrew Winokur , MD, PhD;

11/22/2019

Esketamine Nasal Spray Tolerability Trends During Post-Dose Monitoring in Patients With Treatment-Resistant Depression

Objective: This post hoc analysis assessed (1) whether the first-week incidence of adverse events (AEs) considered most commonly linked to the duration of the post-dose monitoring period ...

Mary Petrillo , PharmD;

Jagadish Gogate , PhD;

H. Lynn Starr , MD, FAAP;

Jennifer Kern Sliwa , PharmD, BCPP;

Ella Daly , MB, BCh, BAO;

David Williamson , PhD, MBA;

Lewis Manera , MS;

03/01/2019